ZV
ZyVersa Therapeutics, Inc.
ZVSA · OTC
$0.10 -12.70% (-$0.01)
1M +13.97%
Market Cap $918.1K
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.1
1.0% upside
Current Price
$0.099
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ZVSA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
0/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 16.54%
ROA 3.30%
Asset turnover 0.00x
Debt
0 /100
High Current ratio 0.05x
Int. coverage -46.93x
Debt/Equity N/A
Stability
48 /100
Moderate Beta 0.87x
EPS volatility 58.45%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ZVSA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephen C. Glover
Employees
6
Headquarters
Weston
Upcoming events
18 NOV
Earnings
Upcoming earnings report